Mesenchymal Stem Cells Therapies on Fibrotic Heart Diseases
Stem cell therapy is a promising alternative approach to heart diseases. The most prevalent source of multipotent stem cells, usually called somatic or adult stem cells (mesenchymal stromal/stem cells, MSCs) used in clinical trials is bone marrow (BM-MSCs), adipose tissue (AT-MSCs), umbilical cord (...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/14/7447 |
| _version_ | 1797526966215114752 |
|---|---|
| author | Fernanda Gubert Jaqueline Soares da Silva Juliana F. Vasques Renata Guedes de Jesus Gonçalves Robertta Silva Martins Mauro Paes Leme de Sá Rosalia Mendez-Otero Gisele Zapata-Sudo |
| author_facet | Fernanda Gubert Jaqueline Soares da Silva Juliana F. Vasques Renata Guedes de Jesus Gonçalves Robertta Silva Martins Mauro Paes Leme de Sá Rosalia Mendez-Otero Gisele Zapata-Sudo |
| author_sort | Fernanda Gubert |
| collection | DOAJ |
| description | Stem cell therapy is a promising alternative approach to heart diseases. The most prevalent source of multipotent stem cells, usually called somatic or adult stem cells (mesenchymal stromal/stem cells, MSCs) used in clinical trials is bone marrow (BM-MSCs), adipose tissue (AT-MSCs), umbilical cord (UC-MSCs) and placenta. Therapeutic use of MSCs in cardiovascular diseases is based on the benefits in reducing cardiac fibrosis and inflammation that compose the cardiac remodeling responsible for the maintenance of normal function, something which may end up causing progressive and irreversible dysfunction. Many factors lead to cardiac fibrosis and failure, and an effective therapy is lacking to reverse or attenuate this condition. Different approaches have been shown to be promising in surpassing the poor survival of transplanted cells in cardiac tissue to provide cardioprotection and prevent cardiac remodeling. This review includes the description of pre-clinical and clinical investigation of the therapeutic potential of MSCs in improving ventricular dysfunction consequent to diverse cardiac diseases. |
| first_indexed | 2024-03-10T09:37:48Z |
| format | Article |
| id | doaj.art-f522e52b7c62449e9dc1b3cd6db5f7fa |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T09:37:48Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-f522e52b7c62449e9dc1b3cd6db5f7fa2023-11-22T03:58:43ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-07-012214744710.3390/ijms22147447Mesenchymal Stem Cells Therapies on Fibrotic Heart DiseasesFernanda Gubert0Jaqueline Soares da Silva1Juliana F. Vasques2Renata Guedes de Jesus Gonçalves3Robertta Silva Martins4Mauro Paes Leme de Sá5Rosalia Mendez-Otero6Gisele Zapata-Sudo7Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21944-590, BrazilPrograma de Pesquisa em Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21944-590, BrazilPrograma Redes de Pesquisa em Saúde no Estado do Rio de Janeiro, Rio de Janeiro 21944-590, BrazilPrograma Redes de Pesquisa em Saúde no Estado do Rio de Janeiro, Rio de Janeiro 21944-590, BrazilPrograma Redes de Pesquisa em Saúde no Estado do Rio de Janeiro, Rio de Janeiro 21944-590, BrazilInstituto do Coração Edson Saad, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21944-590, BrazilPrograma Redes de Pesquisa em Saúde no Estado do Rio de Janeiro, Rio de Janeiro 21944-590, BrazilPrograma de Pesquisa em Desenvolvimento de Fármacos, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21944-590, BrazilStem cell therapy is a promising alternative approach to heart diseases. The most prevalent source of multipotent stem cells, usually called somatic or adult stem cells (mesenchymal stromal/stem cells, MSCs) used in clinical trials is bone marrow (BM-MSCs), adipose tissue (AT-MSCs), umbilical cord (UC-MSCs) and placenta. Therapeutic use of MSCs in cardiovascular diseases is based on the benefits in reducing cardiac fibrosis and inflammation that compose the cardiac remodeling responsible for the maintenance of normal function, something which may end up causing progressive and irreversible dysfunction. Many factors lead to cardiac fibrosis and failure, and an effective therapy is lacking to reverse or attenuate this condition. Different approaches have been shown to be promising in surpassing the poor survival of transplanted cells in cardiac tissue to provide cardioprotection and prevent cardiac remodeling. This review includes the description of pre-clinical and clinical investigation of the therapeutic potential of MSCs in improving ventricular dysfunction consequent to diverse cardiac diseases.https://www.mdpi.com/1422-0067/22/14/7447mesenchymal stem cellscardiac fibrosiscardiovascular diseases |
| spellingShingle | Fernanda Gubert Jaqueline Soares da Silva Juliana F. Vasques Renata Guedes de Jesus Gonçalves Robertta Silva Martins Mauro Paes Leme de Sá Rosalia Mendez-Otero Gisele Zapata-Sudo Mesenchymal Stem Cells Therapies on Fibrotic Heart Diseases International Journal of Molecular Sciences mesenchymal stem cells cardiac fibrosis cardiovascular diseases |
| title | Mesenchymal Stem Cells Therapies on Fibrotic Heart Diseases |
| title_full | Mesenchymal Stem Cells Therapies on Fibrotic Heart Diseases |
| title_fullStr | Mesenchymal Stem Cells Therapies on Fibrotic Heart Diseases |
| title_full_unstemmed | Mesenchymal Stem Cells Therapies on Fibrotic Heart Diseases |
| title_short | Mesenchymal Stem Cells Therapies on Fibrotic Heart Diseases |
| title_sort | mesenchymal stem cells therapies on fibrotic heart diseases |
| topic | mesenchymal stem cells cardiac fibrosis cardiovascular diseases |
| url | https://www.mdpi.com/1422-0067/22/14/7447 |
| work_keys_str_mv | AT fernandagubert mesenchymalstemcellstherapiesonfibroticheartdiseases AT jaquelinesoaresdasilva mesenchymalstemcellstherapiesonfibroticheartdiseases AT julianafvasques mesenchymalstemcellstherapiesonfibroticheartdiseases AT renataguedesdejesusgoncalves mesenchymalstemcellstherapiesonfibroticheartdiseases AT roberttasilvamartins mesenchymalstemcellstherapiesonfibroticheartdiseases AT mauropaeslemedesa mesenchymalstemcellstherapiesonfibroticheartdiseases AT rosaliamendezotero mesenchymalstemcellstherapiesonfibroticheartdiseases AT giselezapatasudo mesenchymalstemcellstherapiesonfibroticheartdiseases |